I agree with you but I believe they don't care, because they own 40-46% and don't have to put out any effort in gaining FDA and market approval. They are just sitting back waiting on a buyout and for sure not many know the relationship between itbra and LLBO and they are thinking is darn that's a private company Great to have CISCO backing them
nice and thought out. there are two thought processes as i see this. one is whether the whole technology works as i believe and the other is whether llbo has enough of a piece to make it worth holding. if it was clear we'd be much higher in pps. that's the math and if holmes or someone at llbo came and said it this would be something or nothing. why he/they dont is perplexing. long but frustrated.
OUTSTANDING POST Ibcnu.. ( MM#1 ) Excellent POINT. Fair assessment. Imo.. Whether Jim ( END GAME ) is a BUY-OUT or not is beside the point. His PRIORITY is to LLBO as a whole and to shareholders as well. There's absolutely no reason for not REPORTING or UPDATING the status of LLBO to shareholders. Again.. Why is it that CI/CA has NO PROBLEM informing their own shareholders? But, Jim cannot? Just wondering here. I believe.. Jim is the #1 REASON why potentially new investors are too NERVOUS to go all-in with LLBO. GLTUA..
Great. I too long here since 3 years. I differ with post on company communication. Company has provided already good news if we see carefully. If they have good products in market, then people will realize and stocks can go for stable nice position. I saw couple of stocks went very high without any major news and exploded on final mega news. I am still here ling term.
Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results. CI’s predictive analytic artificial intelligence (AI) based technology now demonstrates 80%+ accuracy with a two-hour wear when compared with the original trials which required 48-hour wear and achieved 74% accuracy. CI and CA expect this greatly improved performance to support the use of the 510(k) approval to launch the technology and products into regulated countries in the near term.
On top of that they are preparing for License and Cooperation Agreement with Asia market.
CI has entered into a License and Cooperation Agreement Cyrcadia Asia, Ltd. (CA), a newly formed company in Hong Kong which will serve as the base for the Asia market launch of CI’s proprietary iTBraTM technology expected to commence in late 2017 or early 2018 under the global CI brand of Cyrcadia Health.
News 
Market Data 
Discover 
